Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31291456 | 0.72 | LMNA (0.32) | EGLN2TSHRLMNA | |
| SCHEMBL31291361 | 0.72 | TP53 (0.34) | ALDH1A1KDM4EHPGD | |
| SCHEMBL24284142 | 0.71 | ALDH1A1 (0.38) | ALDH1A1ENPP1EGLN2HSD17B10KDM4E | |
| SCHEMBL19761056 | 0.71 | EGLN2 (0.36) | ALDH1A1ENPP1EGLN2KDM4EPKM | |
| SCHEMBL23030290 | 0.68 | MAPK1 (0.38) | ALDH1A1ENPP1EGLN2MAPK1TSHR | |
| SCHEMBL31329862 | 0.68 | ALDH1A1 (0.33) | ALDH1A1ENPP1EGLN2KDM4E | |
| SCHEMBL17430752 | 0.67 | EGLN2 (0.42) | ALDH1A1ENPP1EGLN2HSD17B10KDM4E | |
| SCHEMBL24284140 | 0.67 | MBOAT4 (0.36) | ALDH1A1ENPP1EGLN2HSD17B10ADORA2A | |
| SCHEMBL16848682 | 0.64 | L3MBTL1 (0.38) | ADORA2A | |
| SCHEMBL31009759 | 0.64 | ABL1 (0.34) | ALDH1A1EGLN2MAPK1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719592-A1 | BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION | Centennial Therapeutics, LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249612-A1 | BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION | CENTENNIAL THERAPEUTICS, LLC (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20230391795-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-12-07 | — | — | US | disclosed |
| EP-4236938-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116600803-A | Macrocyclic urea orexin receptor agonists | 默沙东有限责任公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2022094012-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022094012-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391795-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | ALDH1A1 2926/4885ENPP1 3835/4885EGLN2 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.